Form 4: Esperion Therapeutics' General Counsel Acquires Shares and Options

Benjamin Looker, General Counsel of Esperion Therapeutics, acquired shares and stock options in a transaction dated March 14, 2025.

Summary

• On March 14, 2025, Benjamin Looker, the General Counsel of Esperion Therapeutics, acquired 224,000 shares of common stock at $0 and 201,000 stock options with an exercise price of $1.50.
• The stock options vest over a four-year period in equal quarterly installments, starting on June 15, 2025.
• Following the transaction, Looker directly owns 407,663 shares of common stock and 201,000 stock options.
• The transactions were reported via a Form 4 filing with the SEC.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard insider transaction. The acquisition of shares and options could be seen as a positive signal, but it's a routine part of executive compensation.

Positives

• The acquisition of shares and options by a company officer can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The stock options will vest over a four-year period, suggesting a long-term commitment from the executive.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions. These filings are closely watched by investors to gauge management's sentiment and confidence in the company.

Comparison to Industry Standards

• Stock option grants and share acquisitions are common forms of executive compensation in the pharmaceutical industry.
• Companies like Amgen, Regeneron, and Vertex Pharmaceuticals also utilize stock options and restricted stock units as part of their compensation packages to align executive interests with shareholder value.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a key executive.

Key Dates